The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1

被引:37
作者
Papp, Z [1 ]
Babiuk, LA [1 ]
Baca-Estrada, ME [1 ]
机构
[1] Univ Saskatchewan, Vet Infect Dis Org, Saskatoon, SK S7N 5E3, Canada
基金
英国医学研究理事会; 加拿大自然科学与工程研究理事会;
关键词
recombinant adenovirus; adenovirus-specific immunity; mucosal;
D O I
10.1016/S0264-410X(98)00279-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We investigated whether pre-existing adenovirus-specific immunity influenced the development of immunity to a foreign antigen expressed by recombinant adenovirus. Active adenovirus-specific immunity was induced in cotton rats by i.n. administration of wild type human adenovirus type 5 (HAd5) two weeks before immunisation with a HAd5 vector expressing the glycoprotein D (gD) of bovine herpesvirus type 1 (gD-dE3 recombinant adenovirus). Active adenovirus-specific immunity inhibited gD-specific immune responses, following either i.n. or gastrointestinal immunisation with gD-dE3. An inhibitory effect was present even if infection with HAd5 and immunisation with gD-dE3 were 13 weeks apart. Passive transfer of adenovirus specific antibodies to cotton rats one day before immunisation, however, did not significantly inhibit gD-specific immune responses induced by i.n. immunisation with gD-dE3. Repealed administration of an adenovirus vector, therefore, may have a limited ability to deliver antigen, while passive immunity to adenovirus may not interfere with the success of immunisation. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:933 / 943
页数:11
相关论文
共 28 条
[1]   PROTECTIVE EFFICACY OF A RECOMBINANT VACCINIA VIRUS IN VACCINIA-IMMUNE MICE [J].
ANDREW, ME .
IMMUNOLOGY AND CELL BIOLOGY, 1989, 67 :339-341
[2]  
BACAESTRADA ME, 1995, IMMUNOLOGY, V86, P134
[3]  
BOUT A, 1994, GENE THER, V1, P385
[4]   EVALUATION OF REPEAT ADMINISTRATION OF A REPLICATION DEFICIENT, RECOMBINANT ADENOVIRUS CONTAINING THE NORMAL CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CDNA TO THE AIRWAYS OF INDIVIDUALS WITH CYSTIC-FIBROSIS [J].
CRYSTAL, RG ;
MASTRANGELI, A ;
SANDERS, A ;
COOKE, J ;
KING, T ;
GILBERT, F ;
HENSCHKE, C ;
PASCAL, W ;
HERENA, J ;
HARVEY, BG ;
HIRSCHOWITZ, E ;
DIAZ, D ;
RUSSI, T ;
PACHECO, F ;
SIKAND, V ;
BRION, P .
HUMAN GENE THERAPY, 1995, 6 (05) :667-703
[5]   Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector [J].
Dong, JY ;
Wang, DH ;
VanGinkel, FW ;
Pascual, DW ;
Frizzell, RA .
HUMAN GENE THERAPY, 1996, 7 (03) :319-331
[6]  
GRAHAM FL, 1991, METHODS MOL BIOL, V7
[7]   RECOMBINANT VACCINIA IMMUNIZATION IN THE PRESENCE OF PASSIVELY ADMINISTERED ANTIBODY [J].
JOHNSON, MP ;
MEITIN, CA ;
BENDER, BS ;
SMALL, PA .
VACCINE, 1993, 11 (06) :665-669
[8]   Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung [J].
Kaplan, JM ;
Armentano, D ;
Sparer, TE ;
Wynn, SG ;
Peterson, PA ;
Wadsworth, SC ;
Couture, KK ;
Pennington, SE ;
StGeorge, JA ;
Gooding, LR ;
Smith, AE .
HUMAN GENE THERAPY, 1997, 8 (01) :45-56
[9]  
KOZARSKY KF, 1994, J BIOL CHEM, V269, P1
[10]   VACCINATION WITH 2 DIFFERENT VACCINIA RECOMBINANT VIRUSES - LONG-TERM INHIBITION OF SECONDARY VACCINATION [J].
KUNDIG, TM ;
KALBERER, CP ;
HENGARTNER, H ;
ZINKERNAGEL, RM .
VACCINE, 1993, 11 (11) :1154-1158